Pulmonary Hypertension Due to Left Heart Disease

被引:70
作者
Al-Omary, Mohammed S. [1 ,2 ]
Sugito, Stuart [1 ]
Boyle, Andrew J. [1 ,2 ]
Sverdlov, Aaron L. [1 ,2 ]
Collins, Nicholas J. [1 ,2 ]
机构
[1] John Hunter Hosp, Cardiovasc Dept, Newcastle, NSW, Australia
[2] Univ Newcastle, Sch Med & Publ Hlth, Univ Dr, Callaghan, NSW, Australia
关键词
cardiac catheterization; heart failure; hypertension; pulmonary; pulmonary wedge pressure; vascular remodeling; PRESERVED EJECTION FRACTION; SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN RECEPTOR ANTAGONISM; DIASTOLIC PRESSURE-GRADIENT; EXERCISE CAPACITY; FAILURE PATIENTS; DOUBLE-BLIND; ARTERY PRESSURE; PHOSPHODIESTERASE-5; INHIBITION; CONTRACTILE FUNCTION;
D O I
10.1161/HYPERTENSIONAHA.119.14330
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common type of PH and is defined as mean pulmonary artery systolic pressure of >20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.
引用
收藏
页码:1397 / 1408
页数:12
相关论文
共 120 条
[1]   Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial [J].
Abraham, William T. ;
Stevenson, Lynne W. ;
Bourge, Robert C. ;
Lindenfeld, Jo Ann ;
Bauman, Jordan G. ;
Adamson, Philip B. .
LANCET, 2016, 387 (10017) :453-461
[2]   PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY [J].
ABRAMSON, SV ;
BURKE, JF ;
KELLY, JJ ;
KITCHEN, JG ;
DOUGHERTY, MJ ;
YIH, DF ;
MCGEEHIN, FC ;
SHUCK, JW ;
PHIAMBOLIS, TP .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :888-895
[3]   CHAMPION Trial Rationale and Design: The Long-Term Safety and Clinical Efficacy of a Wireless Pulmonary Artery Pressure Monitoring System [J].
Adamson, Philip B. ;
Abraham, William T. ;
Aaron, Mark ;
Aranda, Juan M., Jr. ;
Bourge, Robert C. ;
Smith, Andrew ;
Stevenson, Lynne W. ;
Bauman, Jordan G. ;
Yadav, Jay S. .
JOURNAL OF CARDIAC FAILURE, 2011, 17 (01) :3-10
[4]   Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair [J].
Al-Bawardy, Rasha ;
Vemulapalli, Sreekanth ;
Thourani, Vinod H. ;
Mack, Michael ;
Dai, David ;
Stebbins, Amanda ;
Palacios, Igor ;
Inglessis, Ignacio ;
Sakhuja, Rahul ;
Ben-Assa, Eyal ;
Passeri, Jonathan J. ;
Dal-Bianco, Jacob P. ;
Yucel, Evin ;
Melnitchouk, Serguei ;
Vlahakes, Gus J. ;
Jassar, Arminder S. ;
Elmariah, Sammy .
JAMA CARDIOLOGY, 2020, 5 (01) :47-56
[5]   Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction [J].
Al-Naamani, Nadine ;
Preston, Ioana R. ;
Paulus, Jessica K. ;
Hill, Nicholas S. ;
Roberts, Kari E. .
JACC-HEART FAILURE, 2015, 3 (06) :467-474
[6]  
Amin Ahmad, 2013, Congest Heart Fail, V19, P99, DOI 10.1111/chf.12008
[7]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[8]   Differential Hemodynamic Effects of Exercise and Volume Expansion in People With and Without Heart Failure [J].
Andersen, Mads J. ;
Olson, Thomas P. ;
Melenovsky, Vojtech ;
Kane, Garvan C. ;
Borlaug, Barry A. .
CIRCULATION-HEART FAILURE, 2015, 8 (01) :41-U84
[9]   Relationship Between Reactive Pulmonary Hypertension and Mortality in Patients With Acute Decompensated Heart Failure [J].
Aronson, Doron ;
Eitan, Amnon ;
Dragu, Robert ;
Burger, Andrew J. .
CIRCULATION-HEART FAILURE, 2011, 4 (05) :644-650
[10]   Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension [J].
Assad, Tufik R. ;
Maron, Bradley A. ;
Robbins, Ivan M. ;
Xu, Meng ;
Huang, Shi ;
Harrell, Frank E. ;
Farber-Eger, Eric H. ;
Wells, Quinn S. ;
Choudhary, Gaurav ;
Hemnes, Anna R. ;
Brittain, Evan L. .
JAMA CARDIOLOGY, 2017, 2 (12) :1361-1368